Janux Reports Q3 Results, Plans JANX011 Data
The San Diego biotech reported third-quarter 2026 financials and scheduled initial clinical data for November 9.
Updated on Nov. 5, 2026 in Biotech
Janux Therapeutics, a clinical-stage biopharmaceutical company based in San Diego and listed on Nasdaq as JANX, reported third quarter 2026 financial results on November 5, 2026. The company reported net loss of $21.6 million for the quarter, compared with $24.3 million a year earlier.
Why it matters
The results show Janux's cash position and spending as it advances its clinical pipeline, including early-stage programs in healthy volunteers. Investors and local observers of San Diego's biotech sector will watch the upcoming data for signs of progress.
Research and development expenses were $30.6 million, down from $34.6 million a year earlier, while general and administrative expenses were $10.0 million, compared with $10.6 million. Cash reserves declined from $966.6 million at year-end 2025 to $945.7 million at the end of September 2026.
The players
Janux Therapeutics
A clinical-stage biopharmaceutical company based in San Diego and listed on Nasdaq under the ticker JANX, focused on T-cell engager therapies.
The details
Janux said the first patient has been dosed in a Phase 1 study of JANX013 in combination with JANX007. JANX011, which is designed to achieve deep and durable B-cell depletion while limiting cytokine release, is in a Phase 1 study in healthy volunteers, with initial data to be presented during an investor webcast.
Timeline
September 30, 2026: End of the quarter for reported results.
November 5, 2026: Janux reported third quarter 2026 results.
November 9, 2026: Initial JANX011 clinical data to be presented in an investor webcast.
First half of 2027: Additional JANX007 Phase 1b data expected at a medical congress.
Roadmap
Janux's JANX007 Phase 1b program is set to produce additional data at a medical congress in the first half of 2027. The JANX011 and JANX013 studies extend that clinical effort into new Phase 1 trials.
The November 9 webcast is the next concrete milestone for investors tracking Janux's JANX011 program. Janux's cash runway and pace of clinical spending will determine when the company may need additional funding.
The takeaway
Readers following San Diego's biotech sector can track Janux's November 9 data as a measure of early clinical progress. Cash reserves and quarterly spending offer a simple way to monitor how long the company can fund its programs.
What happens next
Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 will be presented on November 9, 2026, and additional JANX007 Phase 1b data are expected at a medical congress in the first half of 2027.
Further reading
For more on the sector, explore Biotech coverage from San Diego.
Source note: This article includes information reported by Firstwordpharma.
